Publication

Article

Oncology Live®

Vol. 25/No. 10
Volume25
Issue 10

The Importance of Oral Medicine in Cancer: Evaluation and Treatment

Key Takeaways

  • Oral medicine is crucial for managing oral complications in cancer and autoimmune patients, yet remains largely inaccessible.
  • Significant percentages of cancer patients undergoing chemotherapy, stem cell transplants, or head and neck radiation experience oral complications.
SHOW MORE

Alessandro Villa, DDS, PhD, MPH, discusses the importance of oral medicine in cancer treatment.

Alessandro Villa, DDS, PhD, MPH

Alessandro Villa, DDS, PhD, MPH

As an emerging and growing specialty, oral medicine is still largely inaccessible to many patients with cancer, as well as patients with autoimmune or inflammatory conditions. Commonly, patients with these health concerns experience poor quality of life due to mouth sores, pain, burning, mouth dryness, or other oral conditions. However, we know from experience that with appropriate and timely identification of potential problems, we can help eliminate or reduce the incidence and severity of complications attributed to cancer therapy and illness.

Over 2 million new cancer cases are expected to be diagnosed in the US in 2024.1 Among all patients with cancer, approximately 40% who receive chemotherapy, 80% who undergo a stem cell transplant, and 90% of those who received radiation for head and neck malignancies experience oral complications.2

When you consider the number of patients with cancer—along with the conservatively estimated 23.5 million Americans at increased risk for oral health problems due to autoimmune diseases such as lupus, rheumatoid arthritis, Type 1 diabetes, celiac disease, and psoriasis— the need to improve access to oral medicine specialists is clear. It’s also necessary to broaden the understanding of how we can be of benefit to patients.

As the only board-certified cancer center–based oral medicine specialist in South Florida, I care for patients with problems of the lips, roof of the mouth, tongue, salivary glands, and the inner lining of the cheeks. At Miami Cancer Institute, we treat oral lichen planus, aphthous ulcers, dry mouth, jaw osteonecrosis, burning mouth syndrome, temporomandibular disorders, and oral infections (herpes simplex virus and candidiasis), as well as oral precancers, such as leukoplakia, and oral toxicities of targeted therapies and immunotherapies.

Procedures performed include biopsy of oral lesions, intralesional steroid injections, nonsurgical sequestrectomy (of the jawbone), topical and systemic medical treatments, and trigger point injections.

Dental evaluations are particularly important for patients with cancer who are scheduled for bone marrow transplants or head and neck radiation, as an issue in this area during or after treatment can lead to severe complications or death. We are working to build our relationships with the local dental community and have developed a dental education packet for patients to bring to their dentists to obtain x-rays or clearance prior to starting treatment for head and neck cancers.

We urge anyone who has a sore, bump, or colored lesion in the mouth that doesn’t go away, or a dry or painful mouth or canker sore that doesn’t heal, to seek the care of an oral medicine specialist. It’s also our responsibility to continue to educate the public about the importance of receiving the human papillomavirus vaccine because the virus is responsible for the majority of cases of oropharyngeal cancer.

Working together, dentists, primary care providers, and specialists can deliver the best quality care to our medically complex patients, improving quality of life and preventing life-threatening complications.

References:

  1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49. doi:10.3322/ caac.21820
  2. Leukemia & Lymphoma Society. Dental and Oral Complications of Cancer Treatment Facts. September 2016. Accessed July 18, 2024.xw bit.ly/3Y9wuMV
Related Videos
Elizabeth Buchbinder, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Alec Watson, MD
3 experts are featured in this series.
Sangeetha Venugopal, MD, MS, discusses factors that inform JAK inhibitor selection in myelofibrosis.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.
2 experts in this video
2 experts in this video
Sagar D. Sardesai, MBBS